Login to Your Account


GSK Leads Potential $750M Effort to Advance Antibiotics

By Nuala Moran
Staff Writer

Wednesday, May 30, 2012
LONDON – A European initiative to tackle the rising tide of antibiotic resistance has kicked off, with GlaxoSmithKline plc putting up a Phase IIa compound as the first that will be advanced in clinical development as part of the public-private program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription